RELMADA THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.83 USD | +3.51% |
|
-4.25% | -7.49% |
| Mar. 19 | Transcript : Relmada Therapeutics, Inc., 2023 Earnings Call, Mar 19, 2024 | |
| Mar. 19 | Relmada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 520.9 | 624.7 | 105 | 124.6 | 115.6 | - | - |
| Enterprise Value (EV) 1 | 403.8 | 580.2 | 99.65 | 124.6 | -86.98 | -8.276 | -92.99 |
| P/E ratio | -8.42 x | -3.15 x | -0.66 x | -1.26 x | -1.25 x | -1.62 x | -1.65 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | 38.5 x | 3.76 x |
| EV / Revenue | - | - | - | - | - | -2.76 x | -3.02 x |
| EV / EBITDA | -6,637,221 x | -6,809,535 x | -617,990 x | - | - | - | - |
| EV / FCF | -14,519,678 x | - | - | - | - | - | - |
| FCF Yield | -0% | - | - | - | - | - | - |
| Price to Book | 4.96 x | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 16,242 | 27,726 | 30,099 | 30,099 | 30,174 | - | - |
| Reference price 2 | 32.07 | 22.53 | 3.490 | 4.140 | 3.830 | 3.830 | 3.830 |
| Announcement Date | 3/23/21 | 3/23/22 | 3/23/23 | 3/19/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | 3 | 30.76 |
| EBITDA | -60.83 | -85.21 | -161.2 | - | - | - | - |
| EBIT 1 | -60.84 | -125.7 | -161.2 | -103.7 | -115 | -133.3 | -223.4 |
| Operating Margin | - | - | - | - | - | -4,444.17% | -726.13% |
| Earnings before Tax (EBT) 1 | -59.46 | -125.8 | -157 | -98.79 | -111 | -128.1 | -215.6 |
| Net income 1 | -59.46 | -125.8 | -157 | -98.79 | -111.8 | -119.7 | -169.7 |
| Net margin | - | - | - | - | - | -3,989.07% | -551.75% |
| EPS 2 | -3.810 | -7.160 | -5.300 | -3.280 | -3.056 | -2.358 | -2.323 |
| Free Cash Flow | -27.81 | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 3/23/21 | 3/23/22 | 3/23/23 | 3/19/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -42.65 | -34.18 | -38.3 | -45.51 | -38.74 | -38.7 | -28.15 | -26.03 | -22.69 | -26.83 | -26.37 | -28.03 | -29.23 | -31.37 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -42.61 | -34.38 | -39.75 | -39.93 | -39.42 | -37.94 | -26.32 | -25.3 | -22 | -25.17 | -24.65 | -25.7 | -27.1 | -29.5 |
| Net income 1 | -42.61 | -34.38 | -39.75 | -39.93 | -39.42 | -37.94 | -26.32 | -25.3 | -22 | -25.17 | -25.63 | -26.63 | -27.67 | -29.77 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -2.440 | -1.800 | -1.400 | -1.330 | -1.310 | -1.260 | -0.8700 | -0.8400 | -0.7300 | -0.8400 | -0.8600 | -0.9075 | -0.7650 | -0.6550 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/11/21 | 3/23/22 | 5/5/22 | 8/11/22 | 11/10/22 | 3/23/23 | 5/11/23 | 8/8/23 | 11/8/23 | 3/19/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - |
| Net Cash position 1 | 117 | 44.4 | 5.4 | - | 203 | 124 | 209 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | -27.8 | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | 6.460 | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 3/23/21 | 3/23/22 | 3/23/23 | 3/19/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
3.83
USD
Average target price
10.88
USD
Spread / Average Target
+183.94%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.49% | 116M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- RLMD Stock
- Financials Relmada Therapeutics, Inc.
